Download our white paper

 

Complete this form to download G-Rex bioreactors incubated in Heracell™ Vios™ CR CO₂ Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production.

 

For production of human lymphocytes for cell therapy, a contamination control strategy (CCS) is required as part of current Good Manufacturing Practices (cGMP). Evidence of successful CCS approaches will go a long way to ensuring safety, purity, efficacy and quality of a cell therapy. Microbial contamination and non-viable particulate contamination are the top two reasons for FDA injectable pharmaceuticals from 2009 to 2019.